Sign In
Buy IMUX
$13.97
-0.0200 (-0.143%)
At Close: Jul 31, 2026
Immunic eyes transformative year ahead for MS therapy vidofludimus calcium - ICYMI
09:22am, Saturday, 11'th Jan 2025
Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio joined Proactive to discuss the company's progress in advancing its novel therapy vidofludimus calcium. He discussed the significant mil
Immunic eyes key data readout from multiple sclerosis trial in 2025
09:19am, Tuesday, 07'th Jan 2025
Immunic Inc (NASDAQ:IMUX) has reflected on key milestones achieved in 2024, including advancing its novel therapy, vidofludimus calcium, toward key data readouts and securing significant funding to p
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
06:30am, Tuesday, 07'th Jan 2025
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Pha
Immunic, Inc. to Participate in Investor Conference in December
06:30am, Tuesday, 26'th Nov 2024
NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator
Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMI
12:59pm, Saturday, 16'th Nov 2024
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr. Andreas Muehler talked with Proactive about the publication of the company's Phase 1 and Phase 1b clinical trial results for IMU-856 in The Lancet
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet
09:39am, Wednesday, 13'th Nov 2024
Immunic Inc (NASDAQ:IMUX) announced that data from its phase 1/1b clinical trial for IMU-856, a small molecule targeting SIRT6, has been published in The Lancet Gastroenterology & Hepatology. The stud
– Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients – NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology compa
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript
08:37am, Saturday, 09'th Nov 2024
Immunic, Inc. (NASDAQ:IMUX ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Jessica Breu - Vice President Investor Relations and Communications Daniel Vitt - Chief E
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones
08:58am, Thursday, 07'th Nov 2024
Immunic Inc (NASDAQ:IMUX) ended the third quarter with over $59 million in cash to advance its key clinical programs, including its lead candidate, vidofludimus calcium (IMU-838), for multiple scleros
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
06:30am, Thursday, 07'th Nov 2024
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
06:30am, Thursday, 31'st Oct 2024
– Webcast to be Held at 8:00 am ET on November 7, 2024 – NEW YORK , Oct. 31, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally
Immunic to Participate in Industry, Scientific and Investor Conferences in November
06:30am, Tuesday, 29'th Oct 2024
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammat
Immunic Phase 3 MS study advances following positive recommendation from independent committee
09:16am, Tuesday, 22'nd Oct 2024
Immunic Inc (NASDAQ:IMUX) announced a positive outcome from the interim futility analysis of its Phase 3 ENSURE program which is investigating its lead asset vidofludimus calcium in relapsing multiple
– Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met – – IDMC Also Recommended Continuing Trial
Immunic highlights lead asset's promise in multiple sclerosis at ECTRIMS Congress
08:43am, Wednesday, 18'th Sep 2024
Immunic Inc (NASDAQ:IMUX) announced that it is presenting key data for its lead asset vidofludimus calcium at the 40th Congress of the European Committee for Treatment and Research in Multiple Scleros
